Sharon L. Mulvagh

机构：Dalhousie University, Novo Nordisk (Denmark) · ORCID：0000-0002-7377-4053

发表论文 302 篇 · 总被引 11364 次 · h-index 51

代表论文

• Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes (2026 · JAMA Internal Medicine · 被引 12)
• Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction (2025 · JACC Heart Failure · 被引 12)
• Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial (2025 · Diabetes Care · 被引 11)
• Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes (2026 · JAMA Cardiology · 被引 5)
• Women's heart centres: a clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the Heart Failure Association (HFA), and the Association for Acute CardioVascular Care (ACVC) of the ESC (2026 · European Heart Journal · 被引 3)
• Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial (2025 · European Heart Journal · 被引 3)